Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)
China · Delayed Price · Currency is CNY 31.00
+3.90 (14.39%)
Jun 23, 2026, 3:04 PM CST
Hubei Goto Biopharm Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -81.73 | -27.59 | 23.01 | 40.21 | 78.33 |
Depreciation & Amortization | 115.41 | 43.24 | 28.21 | 27.23 | 23.36 |
Other Amortization | 3.33 | 3.31 | 2.83 | 0.81 | - |
Loss (Gain) From Sale of Assets | 1.44 | -0.11 | -0.17 | 0.01 | - |
Asset Writedown & Restructuring Costs | 14.35 | 10.46 | 2.23 | 0.96 | 3.47 |
Loss (Gain) From Sale of Investments | 0.29 | 0.35 | -0.17 | 0.04 | -0 |
Provision & Write-off of Bad Debts | - | 4.22 | 4.45 | 4.87 | - |
Other Operating Activities | 53.56 | 25.09 | 19.79 | 11.52 | 7.76 |
Change in Accounts Receivable | 25.47 | 8.56 | -60.59 | -34.66 | 20.23 |
Change in Inventory | -99.52 | -43.31 | -9.76 | -60.43 | -173.33 |
Change in Accounts Payable | 34.6 | -29.83 | 62.04 | -6.5 | 103.58 |
Change in Other Net Operating Assets | -1.66 | -0.03 | 1.69 | - | - |
Operating Cash Flow | 41.04 | -20.59 | 68.13 | -24.04 | 58 |
Operating Cash Flow Growth | - | - | - | - | 330.46% |
Capital Expenditures | -166.33 | -311.61 | -409.25 | -407.94 | -90.91 |
Sale of Property, Plant & Equipment | 0.18 | 0.12 | - | 0.13 | - |
Investment in Securities | - | - | 15.02 | -48.5 | -14.5 |
Other Investing Activities | - | 17.16 | -8.11 | 0 | - |
Investing Cash Flow | -166.14 | -294.34 | -402.35 | -456.3 | -105.41 |
Short-Term Debt Issued | - | 32 | - | - | - |
Long-Term Debt Issued | 468.38 | 723.59 | 323.2 | 953.57 | 160 |
Total Debt Issued | 468.38 | 755.59 | 323.2 | 953.57 | 160 |
Long-Term Debt Repaid | -326.06 | -434.2 | -319.88 | -250.44 | -156.77 |
Total Debt Repaid | -326.06 | -434.2 | -319.88 | -250.44 | -156.77 |
Net Debt Issued (Repaid) | 142.32 | 321.39 | 3.32 | 703.12 | 3.23 |
Issuance of Common Stock | - | - | - | - | 208.16 |
Common Dividends Paid | -29.83 | -25.69 | -6.09 | -26.91 | -7.58 |
Other Financing Activities | -22.3 | 23.7 | 18.37 | 37.08 | 3.18 |
Financing Cash Flow | 90.19 | 319.4 | 15.59 | 713.3 | 207 |
Foreign Exchange Rate Adjustments | -0.06 | -0.56 | -0.32 | 0.28 | -0.44 |
Net Cash Flow | -34.98 | 3.92 | -318.94 | 233.23 | 159.16 |
Free Cash Flow | -125.29 | -332.2 | -341.12 | -431.98 | -32.91 |
Free Cash Flow Margin | -20.67% | -61.91% | -60.23% | -71.45% | -5.57% |
Free Cash Flow Per Share | -1.09 | -2.89 | -2.97 | -3.76 | -0.31 |
Cash Interest Paid | - | 0.3 | - | - | - |
Cash Income Tax Paid | -33.08 | -47.25 | -39.05 | -13.81 | 17.33 |
Levered Free Cash Flow | -115.99 | -294.86 | 10.86 | -403.28 | -57.11 |
Unlevered Free Cash Flow | -115.99 | -280.17 | 19.1 | -394.73 | -53.87 |
Change in Working Capital | -65.63 | -79.56 | -12.04 | -109.68 | -54.91 |